Capricor Therapeutics Inc (CAPR) financials
Capricor Therapeutics revenue and earnings by year
Capricor Therapeutics's revenue was $22.3 million in the fiscal year to December 31, 2024, down 11.5% from the year before. Net income was -$40.5 million, -181.7% of revenue. Since the fiscal year to December 31, 2016, revenue has grown 23.9% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 9 fiscal years
| Fiscal year to | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 22 | 25 | 3 | 0 | 0 | 1 | 2 | 3 | 4 |
| Revenue growth | -11.5% | 886.8% | 941.8% | -21.1% | -69.1% | -39.9% | -37.3% | -33.3% | — |
| Operating income | -43 | -24 | -30 | -21 | -14 | -8 | -15 | -13 | -17 |
| Operating margin | -191.1% | -95.6% | -1163.9% | -8549.9% | -4412.6% | -769.5% | -917.0% | -482.4% | -424.6% |
| Net income | -40 | -22 | -29 | -20 | -14 | -8 | -15 | 2 | -19 |
| Net margin | -181.7% | -88.5% | -1137.4% | -8175.9% | -4401.9% | -760.4% | -908.9% | 91.2% | -470.3% |
| Diluted EPS | -$1.15 | -$0.83 | -$1.18 | -$0.87 | — | -$2.07 | -$5.21 | $0.80 | -$10.10 |
| Free cash flow | -42 | -28 | 2 | -18 | -11 | -7 | -14 | -14 | -15 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open CAPR in Markets.
See also: CAPR returns
No forecast, no recommendation. This page describes Capricor Therapeutics Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.